Chloroma: Types and Clinical Manifestations in Leukemia
A chloroma, also known as myeloid sarcoma, is a rare manifestation of myeloid leukemia where malignant cells form a solid tumor outside of the bone marrow. While leukemia is typically characterized by the infiltration of blood and marrow, chloromas represent a localized collection of leukemic blasts in extramedullary sites. Because they can appear in various clinical contexts—ranging from a complication of known leukemia to an initial warning sign of systemic disease—understanding their types and associations is critical for accurate diagnosis and treatment.
Chloroma in Acute Leukemia
In the context of acute leukemia, chloromas are uncommon, and precise prevalence rates are not well-established. Even among specialists treating leukemia, these tumors are seen infrequently. However, certain clinical and genetic markers may increase the likelihood of their occurrence.
Patients more prone to developing chloromas often exhibit specific disease features, including:
- FAB Classification Class M2 (French–American–British classification).
- Diagnosis under the 2016 WHO Classification as a separate entity within "Acute myeloid leukemia (AML) and related neoplasms."
- Specific cytogenetic abnormalities, such as t(8;21) or inv(16).
- Myeloblasts that express CD13, CD14, or T-cell surface markers.
- High peripheral white blood cell counts.
Despite these risk factors, chloroma remains an uncommon complication of acute myeloid leukemia (AML). In some instances, a chloroma may appear as the only sign of relapse after a patient has seemingly responded successfully to AML treatment. In these cases, the tumor is not a localized event but an early herald of systemic relapse. Research involving 24 patients with isolated chloromas post-treatment showed a mean interval of 7 months (ranging from 1 to 19 months) before bone marrow relapse occurred.
[ไม่มีภาพประกอบ]
Chloroma in Myeloproliferative and Myelodysplastic Syndromes
Chloromas can also manifest in patients diagnosed with myelodysplastic syndrome (MDS) or myeloproliferative syndromes (MPS). MPS includes conditions such as chronic myelogenous leukemia (CML), polycythemia vera, essential thrombocytosis, or myelofibrosis.
In these patients, the detection of a chloroma serves as de facto evidence that a premalignant condition has transformed into acute leukemia. For example, if a patient with CML develops a chloroma, it is sufficient evidence to indicate that the disease has entered the blast crisis phase, necessitating an immediate shift in treatment strategy.
Chloroma in Eosinophilic Leukemia
A specific and rare form of myeloid sarcoma has been reported in cases of eosinophilic leukemia induced by the FIP1L1-PDGFRA fusion gene. This variant is characterized by the presence of eosinophilia (an abnormally high count of eosinophils, a type of white blood cell).
This specific type of chloroma is clinically distinct because it responds highly successfully to imatinib, the recommended treatment for FIP1L1-PDGFRA fusion gene-induced eosinophilic leukemia, avoiding the need for more aggressive and toxic therapies.
Primary Chloroma
In very rare circumstances, a chloroma may develop without any pre-existing or concurrent diagnosis of acute leukemia, acute promyelocytic leukemia, or MDS/MPS. This is referred to as primary chloroma.
Diagnosing primary chloroma is particularly challenging. However, data indicates that in nearly all reported cases, acute leukemia develops shortly thereafter, with a median time to development of 7 months (ranging from 1 to 25 months). Consequently, primary chloroma is viewed as the initial manifestation of systemic acute leukemia rather than a localized tumor. Treatment is typically aligned with acute leukemia protocols, with specific adjustments if markers indicate a progression toward acute promyelocytic leukemia (AML3).
[ไม่มีภาพประกอบ]
Key Facts
- Chloromas are rare extramedullary tumors composed of leukemic blasts.
- They are associated with specific AML markers like FAB M2 and cytogenetic abnormalities t(8;21) or inv(16).
- In MDS or MPS patients, a chloroma signals transformation into acute leukemia (e.g., blast crisis in CML).
- Primary chloromas usually precede a systemic leukemia diagnosis by a median of 7 months.
- FIP1L1-PDGFRA fusion gene-induced cases are uniquely responsive to imatinib.
| Disease Context | Clinical Significance | Key Characteristics/Markers |
|---|---|---|
| Acute Myeloid Leukemia (AML) | Uncommon complication or sign of relapse | FAB M2, t(8;21), inv(16), high WBC count |
| MDS / MPS | Evidence of leukemic transformation | Indicates 'blast crisis' in CML patients |
| Eosinophilic Leukemia | Specific genetic driver | FIP1L1-PDGFRA fusion; responsive to imatinib |
| Primary Chloroma | Initial manifestation of leukemia | No prior leukemia diagnosis; median 7 months to AML |
Frequently Asked Questions
What is a chloroma?
A chloroma, also known as myeloid sarcoma, is a solid tumor made of myeloid blasts that forms outside of the bone marrow in patients with myeloid leukemia or related blood disorders.
Can a chloroma appear before leukemia is diagnosed?
Yes, this is known as a primary chloroma. In these rare cases, the tumor is the first sign of the disease, and systemic acute leukemia typically develops within a median of 7 months.
What does a chloroma indicate in a patient with Chronic Myelogenous Leukemia (CML)?
In patients with CML, the appearance of a chloroma is considered definitive evidence that the disease has progressed into the blast crisis phase.
Are there specific genetic markers associated with chloromas in AML?
Yes, they are more common in patients with specific cytogenetic abnormalities, such as t(8;21) or inv(16), and those with FAB classification class M2.
How is FIP1L1-PDGFRA fusion gene-induced chloroma treated?
Unlike most myeloid sarcomas that require aggressive chemotherapy, this specific form is treated highly successfully with imatinib.